Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial

REFERENCES

1. 1.↵
   1. Edwards JC,
   2. Szczepanski L,
   3. Szechinski J,
   4. Filipowicz-Sosnowska A,
   5. Emery P,
   6. Close DR,
   7. et al.

   Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572–81.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Cohen SB,
   2. Emery P,
   3. Greenwald MW,
   4. Dougados M,
   5. Furie RA,
   6. Genovese MC,
   7. et al.

   Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793–806.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Emery P,
   2. Fleischmann R,
   3. Filipowicz-Sosnowska A,
   4. Schechtman J,
   5. Szczepanski L,
   6. Kavanaugh A,
   7. et al.

   The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390–400.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Keystone E,
   2. Fleischmann R,
   3. Emery P,
   4. Furst DE,
   5. van Vollenhoven R,
   6. Bathon J,
   7. et al.

   Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896–908.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Emery P,
   2. Breedveld F,
   3. Martin-Mola E,
   4. Pavelka K,
   5. Szczepanski L,
   6. Hagerty D,
   7. et al.

   Relationship between peripheral B cell levels and loss of EULAR response in rheumatoid arthritis patients treated with rituximab [abstract]. Ann Rheum Dis 2007;66 Suppl II:124. OP0233.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Mease PJ,
   2. Keystone E,
   3. Kaell A,
   4. Emery P,
   5. St. Clair EW,
   6. Dougados M,
   7. et al.

   Predicting outcome of a second course of rituximab for rheumatoid arthritis [abstract]. Ann Rheum Dis 2007;66 Suppl II:434. SAT0019.

   OpenUrl
7. 7.↵
   1. Mease P,
   2. Keystone E,
   3. Kaell A,
   4. Emery P,
   5. St. Clair EW,
   6. Dougados M,
   7. et al.

   SDAI and CDAI for predicting outcome of a second course of rituximab for patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2008;67 Suppl II:196. THU0188.

   OpenUrl
8. 8.↵
   1. Bakker MF,
   2. Jacobs JW,
   3. Verstappen SM,
   4. Bijlsma JW

   . Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007;66 Suppl 3:iii56–60.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Dougados M,
   2. Aletaha D,
   3. van Riel P

   . Disease activity measures for rheumatoid arthritis. Clin Exp Rheumatol 2007;5 Suppl 46:S22–9.

   OpenUrl
10. 10.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.

    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.

    OpenUrlPubMed
11. 11.↵
    1. Felson DT,
    2. Anderson JJ,
    3. Boers M,
    4. Bombardier C,
    5. Furst D,
    6. Goldsmith C,
    7. et al.

    American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.

    OpenUrlPubMed
12. 12.↵
    1. Bathon JM,
    2. Martin RW,
    3. Fleischmann RM,
    4. Tesser JR,
    5. Schiff MH,
    6. Keystone EC,
    7. et al.

    A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586–93.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Van Gestel A,
    2. Anderson J,
    3. van Riel P

    . Modified disease activity scores that include 28 joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1999;38:44–8.

    OpenUrlCrossRef
14. 14.↵
    1. Thurlings RM,
    2. Vos K,
    3. Gerlag DM,
    4. Tak PP

    . Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum 2008;58:3657–64.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Emery P,
    2. Mease P,
    3. Rubbert-Roth A,
    4. Curtis J,
    5. Müller-Ladner U,
    6. Gaylis N,
    7. et al.

    Retreatment with rituximab based on a treatment to target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis. American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, Philadelphia, PA, October 17–21, 2009: Presentation 2013.